2019-04-01
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study
Publication
Publication
Haematologica , Volume 104 - Issue 4 p. E151- E153
Additional Metadata | |
---|---|
doi.org/10.3324/haematol.2018.196899, hdl.handle.net/1765/116287 | |
Haematologica | |
Organisation | Department of Hematology |
Hagenbeek, A, Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M, … Kersten, M. J. (2019). Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study. Haematologica, 104(4), E151–E153. doi:10.3324/haematol.2018.196899 |